OLFML2A Antibody

What is OLFML2A and why is it significant in cancer research?

OLFML2A (Olfactomedin-like protein 2A, also known as Photomedin-1) is a glycoprotein belonging to subfamily IV of the olfactomedin domain-containing (OLFM) proteins. It was first identified and characterized in the mouse retina . OLFML2A has gained significant attention in cancer research due to its overexpression in multiple malignancies, including glioma, acute myeloid leukemia (AML), triple-negative breast cancer (TNBC), and liver hepatocellular carcinoma (LIHC) . Importantly, high OLFML2A expression correlates with poor prognosis in these cancers, making it a potential biomarker and therapeutic target .

What are the typical applications for OLFML2A antibodies in cancer research?

OLFML2A antibodies have multiple research applications including:

• Western blotting (WB) for detecting OLFML2A protein levels in cell and tissue lysates

• Immunofluorescence/Immunocytochemistry (IF/ICC) for cellular localization studies

• Immunohistochemistry (IHC) for analyzing OLFML2A expression in patient tissue samples and correlating with pathological grades

• Mechanistic studies investigating OLFML2A's role in signaling pathways such as Wnt/β-catenin

Which cell lines are commonly used for OLFML2A research?

Based on published research, common cell lines for OLFML2A studies include:

• Glioma cell lines: U87MG and U251 (extensively documented in mechanistic studies)

• Triple-negative breast cancer (TNBC) cell lines (mentioned in relation to OLFML2A's role in proliferation and migration)

• RAW264.7 cells (used in antibody validation as shown in western blot data)

• A549 cells (used in immunofluorescence validation)

How should I optimize Western blot conditions for OLFML2A detection?

For optimal Western blot detection of OLFML2A:

• Expected molecular weight: 73 kDa (confirmed in multiple antibody validations)

• Recommended dilution: Start with 1/500 to 1/1000 for most commercial antibodies

• Sample preparation: Total cell lysates from cancer cell lines such as RAW264.7 or U87MG at approximately 30 μg protein loading

• Controls: Include a peptide competition assay or OLFML2A-knockdown lysates to confirm specificity

• Sample types: Human and mouse samples have been successfully detected with available antibodies

What are effective approaches for silencing OLFML2A expression in experimental settings?

Based on successful published approaches:

• Lentivirus-based shRNA strategy:

  • Multiple published studies have effectively used lentiviral delivery of OLFML2A-shRNA to knockdown expression

  • Infection efficiency should be >80% as monitored by GFP expression

  • Two distinct shRNA sequences targeting different OLFML2A regions are recommended to control for off-target effects

  • Expected knockdown efficiency: >80% reduction at both mRNA (confirmed by qRT-PCR) and protein levels (verified by Western blot)

• Verification of knockdown efficiency:

  • qRT-PCR for mRNA levels (typically shows 70-90% reduction)

  • Western blotting for protein levels (often shows more complete suppression)

How can I effectively analyze OLFML2A expression in patient samples for prognostic studies?

For prognostic studies analyzing OLFML2A in patient samples:

• IHC scoring method:

  • Calculate scores based on both staining intensity and percentage of positive cells

  • Example scoring system: staining intensity (0-3) × percentage of positive cells (0-100%)

  • Establish cutoff values for "high" versus "low" expression based on median values or statistical methods

• Survival analysis:

  • Use Kaplan-Meier method with log-rank test to assess correlation between OLFML2A expression and patient outcomes

  • Report hazard ratios through Cox regression analysis

  • Include relevant clinical parameters (tumor grade, stage, etc.) in multivariate analysis

What is known about the mechanistic role of OLFML2A in cancer progression?

OLFML2A appears to function through multiple mechanisms in cancer progression:

• Wnt/β-catenin pathway regulation:

  • OLFML2A knockdown inhibits Wnt/β-catenin signaling by upregulating amyloid precursor protein (APP) expression

  • This leads to reduced stabilized β-catenin levels and repression of downstream targets (MYC, CD44, and CSKN2A2)

• Cell cycle and apoptosis effects:

  • OLFML2A silencing induces S phase arrest in TNBC cells

  • Promotes apoptosis in multiple cancer types including glioma and TNBC

• EMT and metastasis:

  • shOLFML2A decreases epithelial-mesenchymal transition (EMT) progression in TNBC

  • Affects genes regulating cell movement, cytoskeleton, and invasion

• Signaling pathway interactions:

  • May regulate tumorigenesis through multiple signaling pathways including Wnt, Notch, and hypoxia pathways

  • Inhibits integrin, hepatocyte growth factor (HGF), and nerve growth factor (NGF) signaling pathways

How does OLFML2A expression correlate with immune infiltration in the tumor microenvironment?

Research has identified relationships between OLFML2A and immune infiltration:

• In AML, high OLFML2A expression is associated with extramedullary infiltration

• OLFML2A expression correlates with immune infiltration through the immune microenvironment

• Detailed analysis of TCGA data has been used to study correlations between OLFML2A expression and specific immune cell populations

When designing studies to investigate this relationship:

• Use multiplex immunohistochemistry to co-stain for OLFML2A and immune cell markers

• Analyze transcriptomic data to identify correlations between OLFML2A expression and immune cell signature genes

• Consider in vitro co-culture systems to directly assess how OLFML2A affects immune cell function

What post-translational modifications of OLFML2A have been identified and how might they affect function?

OLFML2A undergoes several post-translational modifications that may regulate its function:

Additional modifications include:

• Potential cleavage at Lys-295 after secretion

• O-glycosylation but not N-glycosylation

These modifications may affect:

• Protein stability and turnover

• Interaction with binding partners

• Localization within the extracellular matrix

• Activation of downstream signaling pathways

How can I address discrepancies between OLFML2A mRNA and protein expression levels in my samples?

Discrepancies between mRNA and protein expression are common and may arise from several factors:

• Post-transcriptional regulation:

  • MicroRNAs targeting OLFML2A mRNA

  • RNA-binding proteins affecting mRNA stability

• Post-translational regulation:

  • Protein degradation pathways (proteasomal or lysosomal)

  • Modifications affecting antibody recognition (consider antibodies targeting different epitopes)

• Technical considerations:

  • RNA quality and extraction method

  • Antibody specificity and sensitivity

  • Detection method differences

Recommended approach:

• Use multiple antibodies targeting different OLFML2A epitopes

• Combine qRT-PCR, Western blot, and immunohistochemistry analysis

• Consider polysome profiling to assess translation efficiency

• Include appropriate positive and negative controls in all experiments

What are the best methods to distinguish between different OLFML2A protein isoforms or family members?

To distinguish between OLFML2A isoforms or related family members:

• Antibody selection:

  • Choose antibodies targeting unique regions not conserved among family members

  • Verify antibody specificity using recombinant proteins of different family members

  • Consider using isoform-specific antibodies when available

• Advanced techniques:

  • Mass spectrometry for precise protein identification

  • RT-PCR with isoform-specific primers

  • Immunoprecipitation followed by Western blot with different antibodies

• Controls for validation:

  • Overexpression systems with tagged constructs of specific isoforms

  • siRNA/shRNA targeting specific isoforms

  • Peptide competition assays

What experimental approaches can resolve contradictory findings about OLFML2A function in different cancer types?

Contradictory findings about OLFML2A function may reflect context-dependent roles. To resolve these contradictions:

• Comprehensive characterization across multiple cancer types:

  • Analyze OLFML2A expression in pan-cancer datasets (TCGA, ICGC)

  • Validate findings in tissue microarrays representing multiple cancer types

  • Consider potential tissue-specific co-factors or binding partners

• Mechanistic investigations:

  • Perform OLFML2A interactome studies in different cellular contexts

  • Investigate downstream pathway activation across cancer types

  • Identify tissue-specific binding partners using proximity ligation assays or mass spectrometry

• In vivo validation:

  • Use cancer-specific conditional knockout models

  • Employ patient-derived xenograft models from different cancer types

  • Conduct careful comparison of experimental conditions including microenvironment factors

• Methodological considerations:

  • Standardize experimental conditions across cancer types

  • Control for genetic background in cell line studies

  • Account for tumor heterogeneity by analyzing multiple regions within samples

What are promising approaches for developing OLFML2A as a therapeutic target?

Based on current knowledge of OLFML2A's role in cancer:

• RNA interference strategies:

  • siRNA or shRNA delivery systems have shown efficacy in preclinical models

  • Nanoparticle-based delivery to enhance targeting and reduce off-target effects

  • Consider combinatorial approaches with standard chemotherapy

• Antibody-based therapeutics:

  • Neutralizing antibodies targeting OLFML2A's functional domains

  • Antibody-drug conjugates to deliver cytotoxic agents to OLFML2A-expressing cells

  • Bispecific antibodies targeting OLFML2A and immune effector cells

• Small molecule inhibitors:

  • Target the interaction between OLFML2A and key binding partners

  • Disrupt downstream signaling pathways such as Wnt/β-catenin

  • Structure-based drug design focusing on the olfactomedin domain

• Combination strategies:

  • OLFML2A inhibition combined with immune checkpoint inhibitors

  • OLFML2A targeting with Wnt pathway inhibitors

  • Integration with personalized medicine approaches based on molecular profiling

How might single-cell analysis advance our understanding of OLFML2A's role in tumor heterogeneity?

Single-cell technologies offer powerful approaches to investigate OLFML2A in tumor heterogeneity:

• Single-cell RNA sequencing:

  • Characterize OLFML2A expression across distinct tumor cell subpopulations

  • Identify co-expression patterns with other cancer-related genes

  • Map OLFML2A expression to specific tumor evolutionary trajectories

• Single-cell proteomics:

  • Analyze OLFML2A protein expression and post-translational modifications at single-cell resolution

  • Correlate with activation of downstream signaling pathways

  • Identify rare cell populations with unique OLFML2A expression patterns

• Spatial transcriptomics/proteomics:

  • Map OLFML2A expression in the spatial context of the tumor microenvironment

  • Correlate with immune cell infiltration patterns

  • Analyze expression at tumor invasion fronts versus tumor core

• Integration with clinical outcomes:

  • Correlate single-cell OLFML2A expression patterns with treatment response

  • Identify resistance-associated OLFML2A expression signatures

  • Develop predictive models for patient stratification